Reunion Neuroscience v. Mindset Pharma — Dismissed With Prejudice After 295 Days
Reunion Neuroscience and its Canadian affiliate sued Mindset Pharma in New Jersey over two patents covering psilocin derivatives and tryptamine prodrugs for CNS disorders. The parties reached a stipulated dismissal with prejudice in under ten months, with each side bearing its own legal costs.
Early stipulated exit in a rare psychedelic-pharma patent clash
Filed on 13 March 2023 in the District of New Jersey, this infringement action pitted Reunion Neuroscience, Inc. and Reunion Neuroscience Canada, Inc. against Mindset Pharma, Inc. — two companies operating in the nascent but rapidly contested space of psychedelic-derived therapeutics. Reunion asserted two granted US patents: US11591353B2, covering psilocin derivatives as serotonergic psychedelic agents for the treatment of CNS disorders, and US11292765B2, directed to tryptamine prodrugs. Both patents sit at the scientific frontier of next-generation mental health therapeutics.
The case closed on 2 January 2024 — just 295 days after filing — via a joint stipulation of dismissal with prejudice. The dismissal was agreed by both parties through their counsel of record: Harvey Bartle IV of Morgan, Lewis & Bockius for the plaintiffs, and Keith J. Miller of Robinson Miller LLC for Mindset Pharma. Crucially, each side agreed to bear its own attorneys’ fees and costs, suggesting a negotiated resolution rather than a unilateral concession by either party.
The speed of resolution — under ten months from filing to stipulated dismissal — is consistent with an early settlement or licensing arrangement reached before substantive claim construction or discovery concluded. The public record does not disclose the terms of any underlying agreement. What remains unknown is whether Mindset Pharma obtained a licence to the asserted patents, agreed to design-around constraints, or whether Reunion concluded that enforcement posed risks to its own patent positions.
Filing to dismissal in 295 days
295 days — resolved well within the median trial timeline for district court patent cases
Stipulated dismissal with prejudice — what it means for both sides
What a stipulated dismissal with prejudice actually means
A dismissal with prejudice entered by stipulation means both parties consented to permanently closing this litigation. Reunion Neuroscience is barred from re-filing the same patent infringement claims — US11591353B2 and US11292765B2 — against Mindset Pharma on the same accused products. The dismissal has the legal force of a final judgment on the merits, even though no court ruling on infringement was ever issued.
Permanent bar on refilingOwn-costs ruling suggests a negotiated exit, not a capitulation
When both parties agree to bear their own costs in a with-prejudice dismissal, it typically signals a negotiated resolution — a licence, co-existence agreement, or commercial settlement — rather than one side simply giving up. Had Mindset Pharma prevailed on invalidity or non-infringement, defendants ordinarily seek cost recovery. The symmetric cost-bearing here suggests value was exchanged privately, though the public record is silent on specific terms.
Likely private settlementUS11591353B2 and US11292765B2 remain in force
Dismissal with prejudice extinguishes this specific litigation but leaves the underlying patents fully intact. US11591353B2 and US11292765B2 continue to be granted, enforceable assets in Reunion Neuroscience’s portfolio. Reunion retains the right to assert either patent against different defendants or different accused products. Competitors in the psilocin derivative and tryptamine prodrug space should treat both patents as live enforcement risks.
Patents remain enforceableOne of the earliest patent disputes in the psychedelic therapeutics sector
This case is among the earliest district court patent infringement actions in the psychedelic-derived medicine space, reflecting rapidly maturing IP portfolios as companies race to protect serotonergic compound chemistries. The willingness of a well-funded plaintiff to file — and then resolve quickly — suggests portfolio enforcement is being used strategically, not just as a litigation tool but as a commercial lever in a sector where partnership and licensing deals are common.
Early-stage sector IP signalFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Reunion Neuroscience, Inc. | Company | Clinical-stage psychedelic therapeutics company — holder of US11591353B2 and US11292765B2Search in Eureka ↗ |
| Defendant | Mindset Pharma, Inc. | Company | Mindset Pharma, Inc. — clinical-stage developer of psychedelic-inspired medicines for CNS disordersSearch in Eureka ↗ |
| Plaintiff counsel | Harvey Bartle , IV | Attorney | Counsel for Reunion Neuroscience, Inc.Search in Eureka ↗ |
| Defendant counsel | Keith J. Miller | Attorney | Counsel for Mindset Pharma, Inc.Search in Eureka ↗ |
| Presiding judge | Judge / | Chief Judge | New Jersey District Court — Chief JudgeSearch in Eureka ↗ |
Stipulation of dismissal — official text
The stipulation language — ‘dismissed, WITH PREJUDICE’ with each party bearing its own fees — is a standard but significant formulation. The with-prejudice term permanently extinguishes Reunion’s right to re-litigate these specific claims against Mindset Pharma. The symmetric cost allocation, however, distinguishes this from a one-sided capitulation; it is consistent with a negotiated resolution in which both parties extracted some value. No court made any finding on infringement, validity, or claim scope.
US11591353B2 & US11292765B2 — Psilocin Derivatives and Tryptamine Prodrugs
US11591353B2 (application US17/833341) covers psilocin derivatives formulated as serotonergic psychedelic agents for the treatment of central nervous system disorders — a rapidly expanding compound class targeting depression, PTSD, and addiction. US11292765B2 (application US17/364047) is directed to tryptamine prodrugs, a complementary chemistry approach that modifies bioavailability and receptor targeting of psychedelic-class molecules. Both applications were filed in 2021–2022, reflecting the surge in IP activity as psychedelic medicine entered mainstream pharmaceutical development.
Together, these two patents give Reunion Neuroscience overlapping coverage across both active psilocin analogue chemistries and their prodrug formulations — a dual-layer strategy that is difficult for competitors to design around without engaging both patent families. For any company advancing serotonergic psychedelic compounds for CNS indications, these patents represent material freedom-to-operate risks, particularly given that Reunion has already demonstrated willingness to enforce them in federal court within approximately one to two years of grant.
Should your CNS programme run an FTO against US11591353B2 and US11292765B2?
Any R&D team working on psilocin analogues, tryptamine-based prodrugs, or serotonergic psychedelic compounds intended for CNS indications should treat these patents as live FTO risks. The claims cover both the active compound chemistries and prodrug modifications — meaning both discovery-stage chemistry and formulation teams may be in scope. Companies with programmes in depression, PTSD, anxiety, or addiction that use psychedelic-class scaffolds are the most directly exposed.
PatSnap Eureka’s FTO Search Agent can map your compound structures and synthetic routes against the claim language of US11591353B2 and US11292765B2, identifying overlapping coverage and prosecution history disclaimers that define the actual scope of risk. Claim monitoring alerts will flag any continuation or divisional applications Reunion files, ensuring your FTO position stays current as the portfolio evolves — critical in a technology space where new claims are still being granted regularly.
Run a freedom-to-operate analysis on US11591353B2 to assess your product’s exposure
Run FTO in Eureka →Similar patent disputes in psychedelic therapeutics and CNS compound IP
PatSnap Eureka tracks related litigation across truck body equipment, vehicle accessories, and comparable infringement actions in the Georgia district system.
What this case signals for the psychedelic therapeutics IP landscape
A fast-resolved patent dispute between two CNS-focused developers reveals how IP enforcement is already shaping competitive dynamics in the psychedelic medicine sector.
Psychedelic pharma patent enforcement has begun — treat it seriously
This case demonstrates that granted patents in the psilocin derivative and tryptamine prodrug space are being actively enforced at the district court level. R&D teams working on serotonergic psychedelic compounds should conduct FTO analysis against Reunion Neuroscience’s portfolio before advancing candidates into development or IND-enabling studies.
Quick resolution suggests licensing is a viable off-ramp in this sector
The sub-ten-month, symmetric-cost dismissal is consistent with a commercial resolution rather than protracted litigation. In an emerging sector where collaboration is common, this pattern suggests patent holders may prefer licensing over lengthy litigation — making early outreach and design-around analysis commercially rational strategies for defendants.
Reunion v Mindset — key questions answered
Reunion Neuroscience, Inc. and Reunion Neuroscience Canada, Inc. filed a patent infringement action against Mindset Pharma, Inc. in the District of New Jersey on 13 March 2023, asserting US11591353B2 and US11292765B2. The case was dismissed with prejudice by joint stipulation on 2 January 2024, with each party bearing its own costs. No court ruling on infringement or validity was issued.
Reunion asserted two granted US patents: US11591353B2, covering psilocin derivatives as serotonergic psychedelic agents for the treatment of CNS disorders (application US17/833341), and US11292765B2, directed to tryptamine prodrugs (application US17/364047). Both patents were filed in 2021–2022 and granted before the litigation commenced.
Dismissal with prejudice permanently bars Reunion Neuroscience from re-filing the same infringement claims under US11591353B2 and US11292765B2 against Mindset Pharma on the same accused products. However, the underlying patents remain in full force and Reunion retains the right to assert them against other defendants or different accused products in future proceedings.
The stipulation that each party bears its own attorneys’ fees and costs is consistent with a negotiated commercial resolution — such as a licence or co-existence agreement — rather than a unilateral withdrawal by one party. In with-prejudice dismissals where one side clearly prevailed, cost recovery is typically sought. The symmetric cost term suggests both parties extracted value, though the public record discloses no specific settlement terms.
Yes. Dismissal of the litigation has no effect on the validity or enforceability of the underlying patents. US11591353B2 and US11292765B2 remain granted, in-force US patents. Reunion Neuroscience can assert either patent against other parties working on psilocin derivatives, tryptamine prodrugs, or related serotonergic compound chemistries for CNS indications.
PatSnap Eureka searches patents and litigation data to answer instantly.